E. Bover

Prostate Cancer Immunotherapy – Strategy with a Synthetic GnRH Based Vaccine Candidate

R. Bringas, L. Fong, G. Guillén, 2012 .

Advancements in Tumor Immunotherapy and Cancer Vaccines 64 2 . Epidemiology of prostate cancer

G. Guillén, E. Pimentel, M. Castro, 2012 .

Anti-GnRH Neutralizing Antibodies Produce Testosterone Ablation and Tumor Shrinkage in Prostate Cancer Models

G. Guillén, H. Garay, O. Reyes, 2020 .

Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate.

I. Zuna, P. Peschke, R. Bringas, 2007, Vaccine.

Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model.

R. Bringas, R. Millar, G. Guillén, 2016, Oncology letters.

Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms.

P. Peschke, R. Bringas, G. Guillén, 2008, Advances in experimental medicine and biology.

IMMUNITY AND PROTECTION ELICITED BY a RECOMBINANT VACCINE AGAINST ENTEROTOXIGENIC E. Coli

J. Fuente, A. Borroto, Roberto Basulto, 1995 .

Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac

R. Bringas, G. Guillén, L. E. Fernández, 2019, Front. Oncol..